Glenmark Pharmaceuticals Ltd.

NSE: GLENMARK | BSE: 532296

Mid-range Performer

Download real time

1990.90 -13.50 (-0.67%)

56.09% Gain from 52W Low

512.6K NSE+BSE Volume

NSE 04 Sep, 2025 3:31 PM (IST)

56,183.4

Market Cap

High in industry

0.7

Beta 1Year

Very Low volatility

Product Launch

Glenmark to launch bioequivalent of Eisai's Halaven injection in US, with annual sales of $66.3 mn See details

Glenmark Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GLENMARK, BSE:532296 Glenmark Pharmaceuticals Ltd.

Is Glenmark Pharmaceuticals Ltd. worth buying?

571 Votes:

Buy 79.33%

Sell 13.66%

Hold 7.01%

RESEARCH REPORTS

Buy SEE REPORTS >

Sell SEE REPORTS >